Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer

FEBS Open Bio

Volumn 5, Issue , 2015, Pages 502-507

  Chen, Jie ^a   Deng, Qiwen ^b   Pan, Yuqin ^b   He, Bangshun ^b   Ying, Houqun ^c   Sun, Huiling ^a   Liu, Xian ^b   Wang, Shukui ^b  

^a NANJING NORMAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

Breast cancer; Inflammation; NLR; Prognosis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MULTIVARIATE ANALYSIS; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW;

EID: 84935830759     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2015.05.003     Document Type: Article

References (42)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
2. Anders C.K., Johnson R., Litton J., Phillips M., Bleyer A. Breast cancer before age 40years. Semin. Oncol. 2009, 36:237-249.
3. Assi H.A., Khoury K.E., Dbouk H., Khalil L.E., Mouhieddine T.H., et al. Epidemiology and prognosis of breast cancer in young women. J. Thorac. Dis. 2013, 5(Suppl. 1):S2-8.
4. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J. Clin. 2014, 64:52-62.
5. Gabriel C.A., Domchek S.M. Breast cancer in young women. Breast Cancer Res. 2010, 12:212.
6. Ferguson N.L., Bell J., Heidel R., Lee S., Vanmeter S., et al. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 2013, 19:22-30.
7. Paul D., Kumar A., Gajbhiye A., Santra M.K., Srikanth R. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed. Res. Int. 2013, 2013:783131.
8. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
9. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
10. Mantovani A., Romero P., Palucka A.K., Marincola F.M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
11. Balkwill F., Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 2010, 87:401-406.
12. Guthrie G.J., Charles K.A., Roxburgh C.S., Horgan P.G., McMillan D.C., et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013, 88:218-230.
13. Yao M., Liu Y., Jin H., Liu X., Lv K., et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco. Targets Ther. 2014, 7:1743-1752.
14. Satelli A., Brownlee Z., Mitra A., Meng Q.H., Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin. Chem. 2015, 61:259-266.
15. Fentiman I.S., Allen D.S. Gamma-glutamyl transferase and breast cancer risk. Br. J. Cancer 2010, 103:90-93.
16. Forget P., Machiels J.P., Coulie P.G., Berliere M., Poncelet A.J., et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann. Surg. Oncol. 2013, 20(Suppl 3):S650-660.
17. Hung H.Y., Chen J.S., Yeh C.Y., Changchien C.R., Tang R., et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int. J. Colorectal Dis. 2011, 26:1059-1065.
18. Keizman D., Gottfried M., Ish-Shalom M., Maimon N., Peer A., et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist 2012, 17:1508-1514.
19. Mallappa S., Sinha A., Gupta S., Chadwick S.J. Preoperative neutrophil to lymphocyte ratio>5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis. 2013, 15:323-328.
20. Sharaiha R.Z., Halazun K.J., Mirza F., Port J.L., Lee P.C., et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann. Surg. Oncol. 2011, 18:3362-3369.
21. Tomita M., Shimizu T., Ayabe T., Nakamura K., Onitsuka T. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res. 2012, 32:3535-3538.
22. Azab B., Bhatt V.R., Phookan J., Murukutla S., Kohn N., et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann. Surg. Oncol. 2012, 19:217-224.
23. Noh H., Eomm M., Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J. Breast Cancer 2013, 16:55-59.
24. Forget P., Bentin C., Machiels J.P., Berliere M., Coulie P.G., et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br. J. Anaesth. 2014, 113(Suppl. 1):i82-87.
25. Dirican A., Kucukzeybek B.B., Alacacioglu A., Kucukzeybek Y., Erten C., et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?. Int. J. Clin. Oncol. 2014.
26. Neofytou K., Smyth E.C., Giakoustidis A., Khan A.Z., Cunningham D., et al. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med. Oncol. 2014, 31:239.
27. Cihan Y.B., Arslan A., Cetindag M.F., Mutlu H. Lack of prognostic value of blood parameters in patients receiving adjuvant radiotherapy for breast cancer. Asian Pac. J. Cancer Prev. 2014, 15:4225-4231.
28. Knobloch K., Yoon U., Vogt P.M. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J. Craniomaxillofac. Surg. 2011, 39:91-92.
29. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151:264-269. P. Group, W264.
30. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin. Trials 1986, 7:177-188.
31. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
32. Azab B., Shah N., Radbel J., Tan P., Bhatt V., et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med. Oncol. 2013, 30:432.
33. Nakano K., Hosoda M., Yamamoto M., Yamashita H. Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer. Anticancer Res. 2014, 34:3819-3824.
34. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
35. Templeton A.J., McNamara M.G., Seruga B., Vera-Badillo F.E., Aneja P., et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2014, 106:dju124.
36. Corthay A. Does the immune system naturally protect against cancer?. Front. Immunol. 2014, 5:197.
37. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
38. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008, 113:1387-1395.
39. Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013, 73:3499-3510.
40. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999, 5:677-685.
41. Kono H., Fujii H., Ogiku M., Hosomura N., Amemiya H., et al. Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice. J. Immunol. 2011, 187:4818-4825.
42. Kuang D.M., Zhao Q., Wu Y., Peng C., Wang J., et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J. Hepatol. 2011, 54:948-955.